BiotechTube

BIVV020

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Haemolytic Anaemia

Conditions

Autoimmune Haemolytic Anaemia

Trial Timeline

Jun 15, 2020 → Jan 6, 2022

NCT ID
NCT04269551

About BIVV020

BIVV020 is a phase 1 stage product being developed by Sanofi for Autoimmune Haemolytic Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04269551. Target conditions include Autoimmune Haemolytic Anaemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04269551Phase 1Completed

Competing Products

20 competing products in Autoimmune Haemolytic Anaemia

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
VAY736NovartisPhase 2/3
65
remibrutinibNovartisPhase 1
33
RO7049665RochePhase 2
52
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51
rilzabrutinib + placeboSanofiPhase 3
76

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84